# Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade

> **NCT03493932** · PHASE1 · COMPLETED · sponsor: **National Institute of Neurological Disorders and Stroke (NINDS)** · enrollment: 21 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** BMS-986016

## Key facts

- **NCT ID:** NCT03493932
- **Lead sponsor:** National Institute of Neurological Disorders and Stroke (NINDS)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-24
- **Primary completion:** 2023-04-21
- **Final completion:** 2023-06-27
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2024-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03493932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03493932, "Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03493932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*